HomeQuestion

Are there any clinical situations in which you consider switching to a subcutaneous formulation of Vedolizumab from IV?

1

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

How would you manage an asymptomatic patient after VCE showing small bowel Crohn's who passes the patency capsule but has retained the video capsule in the distal ileum with minimal surrounding inflammation?

What factors do you consider when a patient with acute severe ulcerative colitis flare responds to inpatient Infliximab, and you are deciding whether to switch to subcutaneous or continue IV maintenance dosing of Infliximab?

Do you routinely check Infliximab levels on day 3 with patients admitted with acute severe ulcerative colitis?

Would you avoid risankizumab in a patient with stricturing Crohn’s complicated by granulomatous bronchiolitis with stenosis who had to stop ustekinumab due to hemoptysis?

What is you approach to C. difficile treatment in patients admitted for acute severe ulcerative colitis (ASUC) with a positive GDH and PCR with a negative EIA for toxins?

Evidence Meets Expertise

For Physicians

Mednet AI
Community

Company

About
Careers
Publications
Blog

Support

FAQs
Code of Conduct
AI Community Guidelines
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.